June 2025

Pfizer, 3SBio in $6B deal for bispecific cancer drug

Pfizer has entered a $6 billion licensing agreement with China's 3SBio for SSGJ-707, a bispecific drug in clinical trials for - More -

Phillips 66 is set to cut the majority of its Los Angeles refinery workforce starting in December, with full closure by Octob - More -